These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6873468)

  • 1. Stable, highly immunogenic mutants of "Salmonella" with two independent, attenuating markers as potential live vaccine and their validity for "Shigella" and other bacteria.
    Linde K
    Dev Biol Stand; 1983; 53():15-28. PubMed ID: 6873468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High-immunogenic mutants of Salmonella with two independently of each other attenuating markers as potential vaccines from bacteria capable of multiplication. I. communication: usefulness of the purin-auxotrophy for the isolation of high-immunogenic and stable double-marker strains (author's transl)].
    Linde K
    Zentralbl Bakteriol A; 1981; 249(2):203-14. PubMed ID: 7023126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preparation of stable Salmonella vaccine strains through combination of 2 independently attenuating markers with no limitation on growth].
    Linde K
    Arch Exp Veterinarmed; 1980; 34(1):19-32. PubMed ID: 6998400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-immunogenic mutants of Salmonella with two independently of each other attenuating markers as potential vaccines from bacteria capable of multiplication. 2. Communication: spontaneous chromosomal resistance against antibiotics as a possibility for isolation of clones with decreased virulence (author's transl)].
    Linde K
    Zentralbl Bakteriol A; 1981 Aug; 249(3):350-61. PubMed ID: 7023132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of live attenuated Salmonella for oral vaccination.
    Chatfield S; Roberts M; Li J; Starns A; Dougan G
    Dev Biol Stand; 1994; 82():35-42. PubMed ID: 7958481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Basic approach to the production of potential vaccine strains of Salmonella, Shigella and Pasteurella, capable of reproduction, using suitable genetic markers].
    Linde K; Wonitzki C; Beer J; Randhagen B; Keller HP
    Z Gesamte Hyg; 1984 Mar; 30(3):141-7. PubMed ID: 6375171
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Testing of bacterial mutants as potential vaccine strains].
    Koch H
    Arch Exp Veterinarmed; 1980; 34(1):43-50. PubMed ID: 6998402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of Salmonella-based vaccination strategies.
    Spreng S; Dietrich G; Weidinger G
    Methods; 2006 Feb; 38(2):133-43. PubMed ID: 16414270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous protection in pigs induced by a plasmid-cured and crp gene-deleted Salmonella choleraesuis live vaccine.
    Chu CY; Wang SY; Chen ZW; Chien MS; Huang JP; Chen JJ; Hong LS; Shiau AL; Tsai JL; Wu CL
    Vaccine; 2007 Oct; 25(41):7031-40. PubMed ID: 17825957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Laboratory-based surveillance of salmonellosis of humans in Germany--safety of Salmonella typhimurium and Salmonella enteritidis live vaccines].
    Rabsch W; Liesegang A; Tschäpe H
    Berl Munch Tierarztl Wochenschr; 2001; 114(11-12):433-7. PubMed ID: 11766271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-immunogenic mutants of Salmonella with two independently of each other attenuating markers as potential vaccines from bacteria capable of multiplication. III. Communication: spontaneous chromosomal resistance against noxes as a possibility for isolation of clones with decreased virulence (author's transl)].
    Linde K; Wonitzki C; Randhagen B
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):478-89. PubMed ID: 7036589
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of attenuated mutants of Pasteurella multocida strain, pathogenic to calves, in experimental mouse model studies. 4. Immunogenicity of selected revertants of temperature-sensitive, streptomycin-dependent mutants as potential vaccine strains].
    Linde K
    Arch Exp Veterinarmed; 1978; 32(6):943-9. PubMed ID: 749742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suisaloral "Dessau"--a Salmonella cholerae suis live vaccine for oral, parenteral and combined applications].
    Schöll W; Grünert G
    Arch Exp Veterinarmed; 1980; 34(1):91-7. PubMed ID: 7416899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The production of an auxotrophic marked, plasmid-cured Salmonella ser. Typhimurium as a live attenuated vaccine.
    Van Der Walt ML; Greeff AS
    Onderstepoort J Vet Res; 1998 Sep; 65(3):213-20. PubMed ID: 9809326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The history of live bacterial vaccines.
    Lindberg AA
    Dev Biol Stand; 1995; 84():211-9. PubMed ID: 7796956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmonella: immune responses and vaccines.
    Mastroeni P; Chabalgoity JA; Dunstan SJ; Maskell DJ; Dougan G
    Vet J; 2001 Mar; 161(2):132-64. PubMed ID: 11243685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed population approach for vaccination with live recombinant Salmonella strains.
    Yan ZX; Meyer TF
    J Biotechnol; 1996 Jan; 44(1-3):197-201. PubMed ID: 8717404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological safety concepts of genetically modified live bacterial vaccines.
    Frey J
    Vaccine; 2007 Jul; 25(30):5598-605. PubMed ID: 17239999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic Potency of a Chimeric Protein Comprising InvH and IpaD against Salmonella and Shigella spp.
    Emami Mahmoudabadi FS; Vakili A; Nazarian S; Amani J; Mousavi Gargari SL
    Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):484-493. PubMed ID: 34418902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.